Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Roivant Sciences

Biotech & Life Sciences · New York City, United States · Founded 2014 Decacorn

Developing transformative medicines faster by building technologies and developing talent in creative ways

Valuation
$16B
Market cap · May/2026
Revenue
$29M
Latest reported FY
Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

9 investors on Roivant Sciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 9 investors entered at this stage
Viking Global Investors
Dexcel Pharma
SK Group
SoftBank Vision Fund
RTW Investments
Founders Fund
QVT Financial LP
NovaQuest Capital Management
SoftBank

Roivant Sciences mafia

Startups founded by Roivant Sciences alumni

Former Roivant Sciences employees who went on to start their own companies. Sorted by Dealroom signal score.

StriveEst. 2022
Vivek RamaswamyUnited States
Signal score91
Club FeastEst. 2020
Christopher MiaoUnited States
Signal score88
Proxima BioEst. 2019
Zachary CarpenterUnited States
Signal score84
Kriya TherapeuticsEst. 2019
Shankar RamaswamyUnited States
Signal score72
The FoodhakEst. 2021
Sakshi Chhabra MittalUnited Kingdom
Signal score65
ZipBioEst. 2022
Roee FarberUnited States
Signal score58
LokavantEst. 2020
JAJohn AlfanoUnited States
Signal score56
Zest HealthEst. 2022
Alex GasnerUnited States
Signal score53

Book a demo to explore the full alumni network →

Global footprint

Where Roivant Sciences has talent and traffic

AI talent share
0.4% of workforce is AI talent
(1 of 228 staff)
Core AI00%
Other AI10.44%
Non-AI workforce22799.56%
Workforce by country
4 countries with
team presence
🇺🇸 United States96.7%
🇨🇭 Switzerland2.2%
🇮🇱 Israel0.5%
🇧🇪 Belgium0.5%
4 countries shown
Web traffic by country
19K monthly visits
across markets
🇺🇸 United States60%
🇬🇧 United Kingdom13.7%
🇯🇵 Japan8.9%
🇫🇷 France7.4%
🇮🇳 India6.8%
Top 5 markets shown

Patent intelligence

$28M patent portfolio · 25 active families

Estimated portfolio value
$28M
0.18% of market cap · 3.6× smaller than top peer Celltrion ($101M)
25 active patent families
Where Roivant Sciences innovates Pharmaceutical drugDiseasePharmacologyTetrahydrothiophenePyridazine

Where Roivant Sciences concentrates vs peers

Each axis is a top-10 topic across Roivant Sciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Roivant Sciences's 17 investments and acquisitions.

Every disclosed deal where Roivant Sciences appeared as a backer or acquirer, 2016–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

17 deals across Roivant Sciences's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Roivant Sciences deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Roivant Sciences's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        17 of 17 deals

        Market sentiment

        What the market is saying about Roivant Sciences

        An AI-synthesized read of the highest-engagement posts about Roivant Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Roivant Sciences on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles